The UK has taken a direct equity position in Isomorphic Labs, with the Sovereign AI Fund joining the London group's Series B round on 12 May 2026. According to the Department for Science, Innovation and Technology and Isomorphic Labs, the company is London-founded and headquartered, and the financing totals $2.1 billion, led by Thrive Capital with participation from Alphabet, GV, MGX, Temasek, CapitalG and the UK fund. (gov.uk) The size of the government's cheque has not been disclosed. DSIT says Sovereign AI typically writes equity cheques of around £1 million to £10 million, so the public money is likely a relatively small slice of a much larger global round, even if the political significance is much bigger than the cash amount. (gov.uk)

For Westminster, this is the more important angle. Sovereign AI was launched on 16 April 2026 as a £500 million vehicle meant to back British AI companies with equity, access to compute, visa support and other state help; its own site says supported firms can receive up to 1 million GPU hours. (gov.uk) Isomorphic is the fund's third direct equity investment since launch, taking the total number of companies backed in some form to nine, according to the official government release. That suggests ministers want more than good headlines around AI leadership; they want a place on the share register when strategically important companies start to scale. (gov.uk)

Isomorphic is not a generic AI label attached to a drug story. The company was founded by Sir Demis Hassabis, who Isomorphic says won the 2024 Nobel Prize in Chemistry for work on AlphaFold 2, and the business has been built around turning protein-structure prediction into something closer to a practical drug design platform. (isomorphiclabs.com) In February, Isomorphic said its in-house drug design engine, IsoDDE, goes beyond AlphaFold 3 in predictive accuracy. The company reported that the system more than doubled AlphaFold 3's accuracy on a difficult protein-ligand benchmark and is being used across multiple therapeutic areas and drug types. In plain terms, the bet is that better predictions at the design stage should cut some of the wasted time and cost that sit early in drug discovery. (isomorphiclabs.com)

There is already some commercial proof behind the science. In January 2024, Isomorphic said collaborations with Eli Lilly and Novartis had potential value of nearly $3 billion excluding royalties, with upfront payments from both partners. The latest round therefore lands behind a company that has already persuaded large pharmaceutical groups to pay for access to its approach, rather than one still searching for a first external customer. (isomorphiclabs.com) That matters because many AI drug businesses are long on promise and short on revenue visibility. Isomorphic's model is starting to look more recognisable in business terms: raise capital, secure blue-chip partners, build an internal pipeline and try to turn technical advantage into repeatable income over time. (isomorphiclabs.com)

The government's role also deserves a sober read. This is not Whitehall trying to replace private investors. It is Whitehall joining a funding syndicate that includes US and Asian capital, using public money to help keep a strategic AI business rooted in Britain while it expands globally. DSIT says all Sovereign AI-backed companies must have a meaningful UK presence and are expected to create jobs here. (isomorphiclabs.com) For Market Pulse UK readers, that is the practical takeaway. The state is no longer only offering grants or speeches to advanced tech firms; it is starting to co-invest alongside private capital in areas such as AI infrastructure and drug discovery. If the model works, more of the company-building upside stays in the UK. If it does not, taxpayers are carrying part of the early risk. (sovereignai.gov.uk)

There is still a long distance between a well-funded platform and an approved medicine, so nobody should confuse a funding round with a clinical result. But as a capital-markets story, the message is clear enough: Britain wants its most promising AI companies to remain British even as they become large enough to pull in global money. Isomorphic now sits near the centre of that push. (isomorphiclabs.com) For investors and SME owners, this is worth watching less for immediate sales figures and more for what it says about the next phase of industrial policy. Public money is being used with venture-style discipline, sitting alongside compute access, visa support and other state help rather than replacing them. That is a sharper, more commercial approach than the usual government innovation playbook. (gov.uk)